Google
ANNX — ANNEXON INC (Healthcare >> Biotechnology)
ANNX FAQ
What is ANNX's ROE?
ANNEXON INC reports a Return on Equity (ROE) of -96.06%.
What is ANNX's dividend yield?
ANNEXON INC offers a dividend yield of 0.00%.
What is ANNX's Deepscope Quality Score?
Deepscope rates ANNX's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy ANNX?
Deepscope's AI Timing Score for ANNX is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does ANNX belong to?
ANNEXON INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 5.29
Price
-0.16
(-2.94%)
Day Change
|
|
|---|
ANNX, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 5.29 |
| PBV / Sector |
4.37 / 4.63
|
| Earning Per Share | -1.16 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
13.26 M
GREAT
|
| Average 1W Daily Value |
15.94 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:08:26 |
| Symbol | ANNX |
| Name | ANNEXON INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 163.84 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 892.94 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1400 Sierra Point Parkway, Brisbane, CA, United States, 94005
Phone: 650 822 5500
Website: https://www.annexonbio.com
Employees: 93
Sector: Healthcare >> Biotechnology
Description: Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
